{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:26:32Z","timestamp":1793064392998,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The study aims to investigate the efficacy of stereotactic body radiation therapy (SBRT) in melanoma patients with oligometastatic disease (OMD), and to assess the prognostic value of the European Society for Radiotherapy and Oncology (ESTRO) and European Organization for Research and Treatment of Cancer (EORTC) nomenclature for these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      This is a single-center, retrospective study including all melanoma patients with OMD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200966) receiving SBRT between 2010 and 2023. Patients were categorized based on the timing of SBRT of OMD according to the ESTRO\/EORTC classification. We analyzed local control, progression-free survival (PFS), overall survival (OS), safety, and prognostic factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median follow-up was 72.5 months. Patients were categorized at the timepoint of SBRT as having de novo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), repeat (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925), or induced (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921) OMD. The most common OMD subcategories were repeat oligorecurrence (33.3%) and metachronous oligorecurrence (16.7%). Concurrent systemic treatment was administered in 30.3% of the patients. Local control rates at 1, 2, and 3 years was 96.3%, 93.2%, and 93,2%, respectively. The median PFS and OS were 7.7 (95% CI 4.9\u201312.4) and 26.5 (95% CI 17.6\u201338.8) months, respectively. No significant differences in PFS or OS were observed between patients with de novo, repeat, or induced OMDs. Similarly, survival outcomes did not differ between patients classified into the oligorecurrence, oligoprogression, or oligopersistence cohorts. However, patients who underwent SBRT targeting all metastatic sites demonstrated significantly improved PFS and OS compared to those with additional non-irradiated lesions (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002, respectively). Moreover, patients with a single metastasis had significantly better PFS and OS than those with 2\u20135 metastases (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021). However, only ECOG performance status remained significant in the multivariable analysis. Additionally, 19 patients (29%) experienced grade 1\u20132 SBRT-related side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SBRT was well tolerated and demonstrated excellent local control rates in melanoma with OMD. Our findings indicate that there was no significant difference in PFS or OS between the OMDs, suggesting that the prognostic implication of the ESTRO\/EORTC classification in melanoma may warrant further evaluation in prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-026-02792-2","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:16:39Z","timestamp":1769739399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Stereotactic body radiation therapy for oligometastatic melanoma: a real-world study of the ESTRO\/EORTC nomenclature"],"prefix":"10.1186","volume":"21","author":[{"given":"Ellen","family":"Heurlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitali","family":"Grozman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Egyhazi Brage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildur","family":"Helgadottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"1","key":"2792_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of Temozolomide versus Dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158\u201366.","journal-title":"J Clin Oncol"},{"key":"2792_CR2","doi-asserted-by":"crossref","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P et al. Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2024 Sep 15.","DOI":"10.1056\/NEJMoa2407417"},{"key":"2792_CR3","doi-asserted-by":"publisher","first-page":"114073","DOI":"10.1016\/j.ejca.2024.114073","volume":"204","author":"D Schadendorf","year":"2024","unstructured":"Schadendorf D, Dummer R, Flaherty KT, et al. COLUMBUS 7-year update: A randomized, open-label, phase III trial of Encorafenib plus binimetinib versus Vemurafenib or Encorafenib in patients with BRAF V600E\/K-mutant melanoma. Eur J Cancer. 2024;204:114073.","journal-title":"Eur J Cancer"},{"key":"2792_CR4","doi-asserted-by":"crossref","unstructured":"Long GV, Carlino MS, McNeil C et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024 Sep 15.","DOI":"10.1016\/j.annonc.2024.08.2330"},{"issue":"22","key":"2792_CR5","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1200\/JCO.2000.18.22.3782","volume":"18","author":"J Manola","year":"2000","unstructured":"Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern cooperative oncology group trials. J Clin Oncol. 2000;18(22):3782\u201393.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2792_CR6","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/oncolo\/oyad073","volume":"28","author":"I Stukalin","year":"2023","unstructured":"Stukalin I, Navani V, Gupta M, et al. Development and validation of a prognostic risk model for patients with advanced melanoma treated with immune checkpoint inhibitors. Oncologist. 2023;28(9):812\u201322.","journal-title":"Oncologist"},{"issue":"1","key":"2792_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR, Oligometastases. J Clin Oncol. 1995;13(1):8\u201310.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2792_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2013.07.026","volume":"82","author":"A Ashworth","year":"2013","unstructured":"Ashworth A, Rodrigues G, Boldt G, et al. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82(2):197\u2013203.","journal-title":"Lung Cancer"},{"issue":"1","key":"2792_CR9","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18\u201328.","journal-title":"Lancet Oncol"},{"key":"2792_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.radonc.2022.01.019","volume":"168","author":"J Willmann","year":"2022","unstructured":"Willmann J, Vlaskou Badra E, Adilovic S, et al. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study. Radiother Oncol. 2022;168:256\u201364.","journal-title":"Radiother Oncol"},{"issue":"5","key":"2792_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.ijrobp.2022.08.026","volume":"114","author":"S Baker","year":"2022","unstructured":"Baker S, Mou B, Jiang W, et al. Validation of the prognostic utility of ESTRO\/EORTC oligometastatic disease classification: A secondary analysis from the Population-Based phase II SABR-5 trial. Int J Radiat Oncol Biol Phys. 2022;114(5):849\u201355.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"2792_CR12","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.21873\/anticanres.14609","volume":"40","author":"HJ Chen","year":"2020","unstructured":"Chen HJ, Tu CY, Hsia TC, et al. Prognostic significance of oligometastatic disease classification by the ESTRO\/EORTC of cancer for patients with lung cancer treated with definitive radical radiotherapy. Anticancer Res. 2020;40(10):5895\u20139.","journal-title":"Anticancer Res"},{"issue":"1","key":"2792_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13014-021-01849-8","volume":"16","author":"P Rogowski","year":"2021","unstructured":"Rogowski P, Trapp C, von Bestenbostel R, et al. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiat Oncol. 2021;16(1):125.","journal-title":"Radiat Oncol"},{"issue":"1","key":"2792_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clon.2021.10.004","volume":"34","author":"L Nicholls","year":"2022","unstructured":"Nicholls L, Chapman E, Khoo V, et al. Metastasis-directed therapy in prostate cancer: prognostic significance of the ESTRO\/EORTC classification in oligometastatic bone disease. Clin Oncol (R Coll Radiol). 2022;34(1):63\u20139.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2792_CR15","doi-asserted-by":"publisher","first-page":"1322515","DOI":"10.3389\/fonc.2024.1322515","volume":"14","author":"V Trentesaux","year":"2024","unstructured":"Trentesaux V, Maiezza S, Bogart E, et al. Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study. Front Oncol. 2024;14:1322515.","journal-title":"Front Oncol"},{"issue":"25","key":"2792_CR16","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-Term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830\u20138.","journal-title":"J Clin Oncol"},{"key":"2792_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/1748-717X-7-164","volume":"7","author":"I Fumagalli","year":"2012","unstructured":"Fumagalli I, Bibault JE, Dewas S, et al. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol. 2012;7:164.","journal-title":"Radiat Oncol"},{"issue":"12","key":"2792_CR18","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez DR, Blumenschein GR Jr., Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672\u201382.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2792_CR19","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic Non-Small-Cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501.","journal-title":"JAMA Oncol"},{"issue":"10185","key":"2792_CR20","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051\u20138.","journal-title":"Lancet"},{"key":"2792_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2021.04.003","volume":"151","author":"JM Versluis","year":"2021","unstructured":"Versluis JM, Hendriks AM, Weppler AM, et al. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. Eur J Cancer. 2021;151:72\u201383.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2792_CR22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s10147-014-0717-z","volume":"19","author":"CW Song","year":"2014","unstructured":"Song CW, Kim MS, Cho LC, et al. Radiobiological basis of SBRT and SRS. Int J Clin Oncol. 2014;19(4):570\u20138.","journal-title":"Int J Clin Oncol"},{"issue":"13","key":"2792_CR23","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S1470-2045(15)00141-2","volume":"16","author":"T Ajithkumar","year":"2015","unstructured":"Ajithkumar T, Parkinson C, Fife K, et al. Evolving treatment options for melanoma brain metastases. Lancet Oncol. 2015;16(13):e486\u201397.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2792_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/0284186X.2022.2079959","volume":"61","author":"E Backlund","year":"2022","unstructured":"Backlund E, Yang M, Grozman V, et al. Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. Acta Oncol. 2022;61(7):869\u201373.","journal-title":"Acta Oncol"},{"issue":"4","key":"2792_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/biomet\/92.4.965","volume":"92","author":"M G\u00f6nen","year":"2005","unstructured":"G\u00f6nen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005;92(4):965\u201370.","journal-title":"Biometrika"},{"issue":"11","key":"2792_CR26","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/jamaoncol.2022.4394","volume":"8","author":"R Olson","year":"2022","unstructured":"Olson R, Jiang W, Liu M, et al. Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial. JAMA Oncol. 2022;8(11):1644\u201350.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2792_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","volume":"22","author":"A Chalkidou","year":"2021","unstructured":"Chalkidou A, Macmillan T, Grzeda MT, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021;22(1):98\u2013106.","journal-title":"Lancet Oncol"},{"key":"2792_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157\u201366.","journal-title":"Radiother Oncol"},{"key":"2792_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1748-717X-6-34","volume":"6","author":"MA Stinauer","year":"2011","unstructured":"Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011;6:34.","journal-title":"Radiat Oncol"},{"issue":"4","key":"2792_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138.","journal-title":"Ann Oncol"},{"issue":"1077","key":"2792_CR31","doi-asserted-by":"publisher","first-page":"20170257","DOI":"10.1259\/bjr.20170257","volume":"90","author":"D Franceschini","year":"2017","unstructured":"Franceschini D, Franzese C, De Rose F, et al. Role of extra cranial stereotactic body radiation therapy in the management of stage IV melanoma. Br J Radiol. 2017;90(1077):20170257.","journal-title":"Br J Radiol"},{"issue":"12","key":"2792_CR32","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1080\/0284186X.2023.2280766","volume":"62","author":"E Backlund","year":"2023","unstructured":"Backlund E, Grozman V, Egyhazi Brage S, et al. Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability. Acta Oncol. 2023;62(12):1921\u201330.","journal-title":"Acta Oncol"},{"issue":"1","key":"2792_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.21873\/anticanres.16803","volume":"44","author":"G Kelemen","year":"2024","unstructured":"Kelemen G, Egyud Z, Dobi A, et al. Survival benefit of stereotactic radiotherapy in the complex management of metastatic melanoma. Anticancer Res. 2024;44(1):205\u201312.","journal-title":"Anticancer Res"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02792-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02792-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02792-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:22:17Z","timestamp":1781630537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02792-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2792"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02792-2","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Swedish Ethical Review Authority (Dnr 2020\u201304163 and Dnr 2023-04981-02), which waived informed consent as most patients were deceased at the time of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KL declares engagement with Astra Zeneca (speakers \u0301 engagement, advisory board) and institutional funding from Amgen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}